ArticleMolecules (Basel, Switzerland)2023
Xanthan-Based Materials as a Platform for Heparin Delivery.
Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Study on the Effect of Structural Modification of Xanthan Gum on Its Synergistic Gelation Performance with Locust Bean Gum.Molecules (Basel, Switzerland) · 2026Article
- Advances in Transdermal Drug Delivery Systems for Antithrombotic Therapy: A Systematic Review.ACS pharmacology & translational science · 2025Review
- Production of Bacterial Exopolysaccharides: Xanthan and Bacterial Cellulose.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin (Hep), with its anticoagulant activity, antiangiogenic and apoptotic effects, and growth factor binding, plays an important role in various biological processes. Formulations as drug delivery systems protect its biological activity, and limit the potential side effects of faulty administration. The objective of this study was to develop novel xanthan-based materials as a delivery carrier for heparin. The materials exhibited remarkable elastic behavior and toughness without any crack development within the network, which also support their application for tissue engineering. It was found that all materials possessed the ability to control the release of heparin, according to the Korsmeyer-Peppas release model. All Hep-containing materials caused significant exchanges of the activated partial thromboplastin time (aPTT) and prothrombin time (PT) parameters, indicating that formulated natural/natural synthetic polymeric networks conserved heparin's biological activity and its ability to interrupt the blood coagulation cascade. The obtained results confirmed that developed materials could be carriers for the controlled release of heparin, with potential applications in topical administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.